Castle Biosciences reported publication in the *Journal of the American Academy of Dermatology* of a prospective, multicenter clinical validation study evaluating its AdvanceAD-Tx gene expression profile test in moderate-to-severe atopic dermatitis. The study found that about 30% of patients were classified as having a “JAK Inhibitor Responder Profile,” and within this group those treated with a JAK inhibitor were more likely to reach EASI-90 at three months (45.5% vs. 8.3%) and had a faster time to response than those treated with Th2-targeted therapies; additional endpoints included vIGA-AD 0, itch, flare status, and DLQI 0. The results have already been presented via publication in JAAD, and the company noted AdvanceAD-Tx had a limited access commercial launch in late 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658078-en) on February 19, 2026, and is solely responsible for the information contained therein.